Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06603805
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-09-10
Brief Title:
Optimal Surgical Approach for Early-Stage Breast Cancer in Chinese Patients Aged 40 Years a Cohort Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Optimal Surgical Approach for Early-Stage Breast Cancer in Chinese Patients Aged 40 Years a Cohort Study
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The optimal surgical treatment option BCSRT versus MAST for young patients with early-stage breast cancer remains debated The present study aims to explore trends in surgical management and compare survival outcomes between BCSRT and MAST in young patients with early-stage breast cancer ultimately providing optimal treatment strategies for Asian populations
Detailed Description:
This study is a unique addition to the current research on young women with early-stage breast cancer aiming to compare the survival outcomes between BCSRT and MAST providing valuable insights into their effectiveness for this group of patients This study enrolled patients at West China Hospital Sichuan University Kaplan-Meier analyses with the log-rank test were applied to compare the locoregional recurrence-free survival LRFS distant metastasis-free survival DMFS breast cancer-specific survival BCSS and overall survival OS Cox multivariate hazard regression was employed to assess hazard ratios HRs between the two groups for survival outcomes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None